MIRA Pharmaceuticals, Inc. (MIRA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $0.76. The rating moved from Neutral to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$0.76
• Last changeMoved from Neutral to Overbought on August 18, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - General

See all overbought Healthcare stocks →

AI analysis

MIRA Pharmaceuticals, Inc. (MIRA) is a microcap, development-stage healthcare company with limited public filings and low liquidity. Valuation is predominantly driven by near-term binary catalysts (clinical readouts, partnerships, financing) and by sector-level demand for biologics/CDMO services; the current mild risk-on market tone provides a modest supportive backdrop. Primary concerns are an unclear cash runway, likely dilution risk, and the high volatility typical of small biotechs, meaning outcomes will be catalyst-dependent and asymmetric in both directions.

Key factors

• Small-cap clinical-stage biotech profile with limited public financial disclosure and absent recent EDGAR updates
• Sector tailwinds for biologics, CDMO/CRO services and diagnostics that could indirectly benefit companies with relevant assets or partnerships
• Catalyst-driven valuation: near-term sensitivity to clinical readouts, licensing, partnerships, or financing events
• Current market tone is mildly risk-on, which can support speculative healthcare names in the near term
• Low liquidity and trading volume typical of microcap biotechs, increasing volatility and bid-ask impacts

Risks

• Unknown cash runway and high probability of equity dilution if additional financing is required
• Binary clinical or regulatory outcomes that can cause large intraday moves
• Competitive pressure from larger pharma, established CDMOs, and platform companies
• Limited public information and governance disclosures increase uncertainty for investors
• Reimbursement and payer dynamics that could affect commercialization prospects for therapeutic products
• Market microstructure risk (low liquidity, wide spreads) leading to execution risk for investors

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.